DDP 38003Alternative Names: DDP-38003; DDP_38003
Latest Information Update: 10 Jan 2017
At a glance
- Originator Oryzon
- Developer European Institute of Oncology; Oryzon
- Class Antineoplastics
- Mechanism of Action Lysine specific demethylase 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Nov 2016 Early research in Cancer in Europe (PO)